摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

伏高利特 | 89651-00-3

中文名称
伏高利特
中文别名
——
英文名称
Voxergolide
英文别名
(2R,4R,7R)-6-methyl-4-(methylsulfanylmethyl)-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene
伏高利特化学式
CAS
89651-00-3
化学式
C16H20N2OS
mdl
——
分子量
288.4
InChiKey
GYUHVILBXXBZDS-DJSGYFEHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    53.6
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
    申请人:AQUESTIVE THERAPEUTICS INC
    公开号:WO2021087359A1
    公开(公告)日:2021-05-06
    Pharmaceutical compositions include a prodrug of epinephrine are described.
    药物组合物包括表述的肾上腺素前药。
  • Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
    申请人:Rogers D. Robin
    公开号:US20070093462A1
    公开(公告)日:2007-04-26
    Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.
    揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法,以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效(协同作用)以及改善易用性和制造工艺。
  • [EN] ARYL IMIDAZOLE COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS<br/>[FR] COMPOSÉ ARYLIMIDAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PRODUCTION DE LA PROTÉINE AMYLOÏDE BÊTA
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098488A1
    公开(公告)日:2010-09-02
    A compound represented by the formula (I): or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a triazolyl group or the like which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物,或其药理学上可接受的盐或酯,其中环A代表可能被取代的三唑基团或类似物,环B代表可能被取代的苯基团或类似物,X1代表单键或类似物,R1和R2分别代表C1-6烷基或类似物,m代表0到3的整数,n代表0到2的整数,对于由Aβ引起的疾病具有治疗作用。
  • MULTI-CYCLIC COMPOUNDS
    申请人:KIMURA Teiji
    公开号:US20090062529A1
    公开(公告)日:2009-03-05
    A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
    一种由化学式(I)表示的化合物或其药理学可接受的盐,其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团,Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团,X1代表双键或类似基团,Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团,对由Aβ引起的疾病具有治疗或预防作用。
  • [EN] NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS CONTENANT DE L'AZOTE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PRODUCTION DE LA BÊTA-AMYLOÏDE
    申请人:EISAI R&D MAN CO LTD
    公开号:WO2010098487A1
    公开(公告)日:2010-09-02
    A compound represented by the formula [I]: or a pharmacologically acceptable salt or ester thereof, wherein Ring A represents a five-membered aromatic heterocyclic group or the like fused with a non-aromatic ring group, which may be substituted, Ring B represents a phenyl group or the like which may be substituted, X1 represents a single bond or the like, R1 and R2 each represent a C1-6 alkyl group or the like, m represents an integer of 0 to 3, and n represents an integer of 0 to 2, is effective as a therapeutic agent for a disease caused by Aβ.
    化合物的分子式为[I]:或其药理学可接受的盐或酯,其中环A代表一个五元芳香杂环基团或类似于非芳香环基团的融合物,可以被取代,环B代表一个苯基或类似的基团,可以被取代,X1代表一个单键或类似物,R1和R2分别代表一个C1-6烷基基团或类似物,m表示0到3的整数,n表示0到2的整数,对由Aβ引起的疾病具有治疗作用。
查看更多

同类化合物

伏高利特 6-乙基-9-氧杂麦角灵 (6aR,10aR)-4,7-二甲基-4,6a,7,8,9,10a-六氢-6H-吲哚并[3,4-gh][1,4]苯并噁嗪乙二酸酯 Trans-7-[2-(4-benzylpiperazin-1-yl)-1-oxoethyl]-4,6,6a,8,9,10a-hexahydro-10a-methyl-4-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine trans-7-chloroacetyl-4,6,6a,8,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine trans-4,6,6a,7,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-indolo[3,4-gh][1.4]benzoxazin-8-one trans-4,6,6a,8,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine 4,6,6a,8,9,10a-hexahydro-10a-methylindolo[3,4-gh][1.4]benzoxazine 4,6a,7,8,9,10a-Hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) 7H-Indolo(3,4-gh)(1,4)benzoxazine, 4,5,5a,6,6a,8,9,10a-octahydro-7-propyl-, (+-)-, (5a-RS(5a-alpha,6a-beta,10a-alpha))- Oxalic acid--5-bromo-7-methyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine (1/1) 7-Propyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) Paspaclavin 7-Methyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) trans-4,6,6a,8,9,10a-hexahydro-7-n-butyl-7H-indolo-[3,4 gh]-[1,4]-benzoxazine trans-4,6,6a,8,9,10a-Hexahydro-7H-indolo-[3,4-gh]-[1,4]-benzoxazine 9-Oxaergoline, 2-bromo-6-propyl-, monohydrochloride, (+-)- 4,6,6a,8,9,10a-Hexahydro-10a-methyl-7-(2-phenoxyethyl)-7H-indolo[3,4-gh][1.4]benzoxazine (6aRS,10aRS)-4,6,6a,8,9,10a-hexahydro-7H-indolo<3,4-gh><1,4>benzoxazine 6-Methyl-4-(methylsulfanylmethyl)-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene (2S,7S)-6-ethyl-15-methoxy-2-methyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraene 10-bromo-6-propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene;hydron;chloride (2R,7R)-6,11-dimethyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene (2R,7R)-10-bromo-6-propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene 5,6-Dimethyl-3-prop-1-en-2-yl-4-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene